Evaluating therapeutic benefits of ubrogepant via latent class models: A post hoc exploratory analysis of the ACHIEVE I and ACHIEVE II trials

CONCLUSION: The LCM approach led to higher rates of treatment success and greater separation between ubrogepant and placebo and was a more sensitive predictor of treatment satisfaction than the regulatory endpoint of 2hPF.PMID:37873925 | DOI:10.1111/head.14631

Source: Headache - October 24, 2023 Category: Neurology Authors: Charlie J Iaconangelo Daniel Serrano Aubrey Manack Adams Joel M Trugman Richard B Lipton Source Type: research